Jonathan Schoenfeld Answers: Which Patients Benefit Most from Immunotherapy and Radiation

Video

Jonathan Schoenfeld discusses the patient profile that would benefit best from a combination of radiation and immunotherapy.

Jonathan Schoenfeld, MD, MPhil, MPH, of Dana-Farber Cancer Institute, discusses which patients would benefit most from a combination of immunotherapy and radiation treatment.

Right now, patients with local or locally-advanced disease, or with suppressed immune systems are not thought to be the best candidates for immunotherapy. However, Schoenfeld believes that will change with the advances being made.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
Photo of a woman with brown hair and a floral blouse
Photo of a woman with a blue border around the image
2 experts are featured in this series.
2 experts are featured in this series.
Image of a woman with gray hair and glasses in front of a blue Oncology Nursing News background
Photo of a woman with blond wavy hair wearing a blazer in front of a blue Oncology Nursing News background
Photo of a woman with shoulder-length blond hair in front of an Oncology Nursing News backdrop
Image of a woman with white hair in front of an Oncology Nursing News blue background
Related Content
doctor in white coat holding hand out with the word "immunotherapy" floating above

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers

Russ Conroy
November 12th 2024
Article

Adding E-602 to cemiplimab demonstrated anti-tumor effects in patients PD-L1–resistant solid cancers.

Ask The Right Questions: Clinical Pearls of AE Management

Ask The Right Questions: Clinical Pearls of AE Management

Lindsay Fischer
February 15th 2022
Podcast

In this episode of “The Vitals,” Mark Honor, PA-C, discusses adverse event management in patients receiving different therapeutic options.

kidney cancer

Atezolizumab Falls Short in Pretreated, Advanced Renal Cell Carcinoma

Gina Mauro
June 17th 2023
Article

The median progression-free survival with atezolizumab to cabozantinib was 10.6 vs 10.8 months with cabozantinib alone.

Immunotherapy in the Age of COVID-19

Immunotherapy in the Age of COVID-19

Brielle Benyon
August 15th 2020
Podcast

Patients With uHCC Who Experience irAEs With Tremelimumab/Durvalumab Achieve Numerical Improvements in OS

Patients With uHCC Who Experience irAEs With Tremelimumab/Durvalumab Achieve Numerical Improvements in OS

Lindsay Fischer
June 3rd 2023
Article

Tremelimumab plus durvalumab (STRIDE) showed a manageable immune-related adverse event profile in the phase 3 HIMALAYA trial.

FDA

Trifluridine/Tipiracil, Plus Bevacizumab Under Priority Review for Refractory mCRC

Kristi Rosa
April 24th 2023
Article

Trifluridine plus tipiracil, with or without bevacizumab, has been granted priority review status for the treatment of refractory, metastatic colorectal cancer.